Bristol-Myers Squibb

Pharmalittle: Merck to halve Keytruda price in China - STAT

What is it?<p>STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with …

Merck

Halozyme Therapeutics To Participate In Upcoming Investor Conference

SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery …

San Diego

Immuno-Oncology Players Gritstone And Sutro Join The Biotech IPO Frenzy

So far, 38 biotechnology companies have gone public in 2018, raising nearly $4 billion, according to figures released by Bloomberg last week. That’s the highest amount the biotech sector has raised on the public markets since 2000, when the science was in its infancy. And if there’s one therapeutic …

Biotechnology

Bristol-Myers Opdivo price in China half of U.S.

STAT News reports that the in-country price of Bristol-Myers Squibb's (BMY -0.3%) Opdivo (nivolumab) in China, approved two months ago for NSCLC, …

Business

Is Bristol-Myers Squibb (BMY) a Great Dividend Play?

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. However, when …

Investing

Bristol-Myers' MM Drug Empliciti Application Validated by EMA

<b>Bristol-Myers Squibb Company</b> BMY announced that the European Medicines Agency (EMA) has validated its type II variation application, seeking approval …

Multiple Myeloma

CTLA4 targeted therapy plus PD-1 targeted therapy could benefit women with ovarian cancer

An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor …

University of Pennsylvania

Gwyneth Paltrow and Chris Martin once tried to stage an intervention for Lily Allen

<b>Lily Allen</b> reveals in her new memoir, <i>My Thoughts Exactly</i>, that <b>Chris Martin</b> and his ex-wife, <b>Gwyneth Paltrow</b>, tried to stage an intervention and get her to seek treatment for alcohol and drug addiction as her life spiraled out of control.<p>The “Smile” singer, 33, details her struggle with substance …

Culver City

Join us for the Seventh Annual Strides for Melanoma Walk for Awareness In 19 Cities across Canada on Sunday, September 23, 2018

OAKVILLE, ON, Sept. 13, 2018 /CNW/ - Melanoma Network of Canada (MNC), the country's leading voice for melanoma patients nationally, will host the seventh annual Strides for Melanoma Walk for Awareness on Sunday, September 23, 2018. The efforts help to raise much needed funds for melanoma patient …

Melanoma

Bristol-Myers Squibb to investigate Natera's ctDNA test as Opdivo biomarker

Natera (NTRA -2.4%) inks an agreement with Bristol-Myers Squibb (BMY +0.6%) under which the latter will evaluate Natera's Signatera custom …

Business

Roche's Child Arthritis Drug's New Formulation Gets FDA Nod

1 / 2<p>Roche (RHHBY) gets FDA approval for the subcutaneous formulation of Actemra for the treatment of active systemic juvenile idiopathic arthritis …

Eli Lilly

Apple under pressure, Tiffany moves higher, Bristol-Myers Squibb dips

Let’s check out the Yahoo Finance charts of the day.<p>Apple (AAPL): Shares are down in early trade. Apple will hold an event today at 1:00 pm PDT at …

Bristol-Myers Squibb

Bristol-Myers Squibb declares $0.40 dividend

Bristol-Myers Squibb (NYSE:BMY) declares $0.40/share quarterly dividend, in line with previous.<p>Forward yield 2.65%<p>Payable Nov. 1; for shareholders of …

Business

Bristol-Myers Squibb's TYK2 inhibitor successful in mid-stage psoriasis study

A Phase 2 clinical trial evaluating Bristol-Myers Squibb's (NYSE:BMY) BMS-986165, a tyrosine kinase 2 (TYK2) inhibitor, in patients with …

Business

CNH Industrial plans euro notes issue

CNH Industrial (NYSE:CNHI) intends to proceed, subject to market conditions, with a benchmark note issuance denominated in Euro.<p>The notes are to be …

Business

Bristol-Myers plaque psoriasis drug shows promise in mid-stage trial

(Reuters) - Bristol-Myers Squibb said on Wednesday its experimental drug helped reduce the severity of the most common form of psoriasis in a mid-stage trial.<p>The study tested the drug, BMS-986165, in 267 patients with plaque psoriasis, a chronic condition that causes dry, red skin lesions covered …

FDA

Stream-of-Commerce Personal Jurisdiction Dries Up Following Bristol-Myers Squibb | Section of Litigation | Section of Litigation / Mass Torts Litigation

Since 2018 began, several decisions have held that <i>Bristol-Myers Squibb Co. v. Superior Court</i>, 137 S. Ct. 1773 (2017) (<i>BMS</i>), precludes theories of …

Lawsuits

Bristol-Myers Reports Positive Results From Phase 2 Study Of BMS-986165

(RTTNews) - Bristol-Myers Squibb Company (BMY) reported results from a Phase 2 study of BMS-986165, an investigational oral, selective tyrosine kinase 2 inhibitor, in patients with moderate to severe plaque psoriasis. The company said efficacy endpoints including =75% and 90% reduction in the …

Lupus

An Early Look At Nektar And Bristol-Myers Squibb's First Combination Phase 3 Trial

<b>Introduction</b><p>In the middle of August, Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) revealed the outline of their phase 3 trial on …

Business

FDA grants priority review to Merck’s sBLA for KEYTRUDA as monotherapy for treatment of locally advanced or metastatic NSCLC

The FDA has accepted for review and granted priority review to Merck's (NYSE:MRK) new sBLA seeking approval for KEYTRUDA, anti-PD-1 therapy, as …

Business

These are the 397 most inspiring, innovative designs of 2018 | Fast Company

Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine International Pediatric AIDS Initiative at Texas Children’s Hospital (BIPAI), Bristol-Myers Squibb Foundation, and CannonDesign

Baylor College of Medicine

A Snapshot Of Bristol-Myers Squibb's Business & Outlook

Bristol-Myers Squibb (NYSE:BMY) generates its revenues from its Oncology, Cardiovascular, Immunology, Virology, along with its Mature Drugs & Other segment. Oncology accounts for over 40% of the company’s total revenues, and will likely see steady growth in the coming years, led by a ramp up in …

Cardiovascular System

Merck's Keytruda clocks up new win as EU approves chemo cocktail

LONDON (Reuters) - Merck & Co’s key cancer drug Keytruda has been approved for use in Europe in combination with chemotherapy in previously untreated lung cancer patients, marking a further advance for the product after uncertainty about its EU prospects a year ago.<p>Keytruda is the first such …

Cancer

Is Bristol-Myers Squibb Company a Buy?

This big pharma stock has some baggage, but it also claims two fast-growing blockbusters.<p><b>Bristol-Myers Squibb</b> (NYSE:BMY) stock has underperformed the</b> …

Investing

Najah Woodby, Lawrence Phillips

Najah Woodby and Lawrence Omar Phillips were married Sept. 8 at the Old Whaling Church in Edgartown, Mass. Jordan Rice, the lead pastor of Renaissance Church in Harlem, officiated.<p>Ms. Phillips, 31, works in New York as a marketing manager for L’Oréal, the cosmetics company. She graduated from Emory …

Management Consulting

Roche's Tecentriq sBLA Review For NSCLC Gets Extended by FDA

1 / 2<p>The FDA extends the review period for Roche's sBLA for Tecentriq in combination with Avastin for the initial treatment of NSCLC by three</b> …

Bristol-Myers Squibb

Here's Why Nektar Therapeutics Jumped 26.4% in August

Investors are regaining their confidence in the high-flying oncology company.<p>What happened<p>Shares of <b>Nektar Therapeutics</b> (NASDAQ:NKTR) rose 26.4% in …

Investing

Bristol-Myers Squibb And NASH: Where Do We Stand?

<b>If you think education is expensive, try ignorance -</b> <b>Derek Bok</b><p><b>Investment Thesis</b><p>Bristol-Myers Squibb Company (BMY) is a multi-billion ($99B) large …

Business

The 6th International Symposium on Transformative Bio-Molecules (ISTbM-6)

ISTbM-6 with the 14th Hirata Award and the 4th Tsuneko and Reiji Okazaki Award<p>Nagoya University's Institute of Transformative Bio-Molecules (ITbM) …

Nagoya

Biotechs and biopharmas in the red

Biotechs and Big Pharma players are getting roughed up as the session heads into the lunch hour. The SPDR S&P Biotech ETF (XBI -2.5%) has lost over …

Business